JP Morgan Chase
PSTV icon

JP Morgan Chase’s Plus Therapeutics PSTV Stock Holding History

JP Morgan Chase’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4
Closed -$146 – 7665
2024
Q3 		$146 Hold
4
– – ﹤0.01% 6949
2024
Q2 		$147 Hold
4
– – ﹤0.01% 6830
2024
Q1 		$181 Hold
4
– – ﹤0.01% 6818
2023
Q4 		$177 Buy
+4
New +$160 ﹤0.01% 7063
2023
Q3 		– Hold
0
– – – 7393
2023
Q1 		– Hold
0
– – – 7126
2022
Q4 		– Hold
0
– – – 6905
2016
Q4 		– Hold
0
– -$2K – 5104
2016
Q3 		– Hold
0
– – – 4436
2013
Q4 		– Hold
0
– -$34K – 4204
2013
Q3 		– Hold
0
– – – 4288
2013
Q2 		– Hold
0
– – – 4210

Other funds holding PSTV

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

JP Morgan Chase's PSTV Position: Q4 2024 in Review

JP Morgan Chase sold out of Plus Therapeutics (PSTV) in Q4 2024, closing a stake of 4 shares — an estimated $146 sold.

JP Morgan Chase first reported a position in PSTV in Q4 2023 and held it in 4 quarters. The position peaked at $181 in Q1 2024. 9 funds tracked by Wall St. Rank hold PSTV as of Q4 2024.

  • JP Morgan Chase reported no remaining Plus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 4 Plus Therapeutics shares in Q4 2024, an estimated $146.
  • JP Morgan Chase first reported a position in Plus Therapeutics in Q4 2023 and held it in 4 quarters.
  • JP Morgan Chase's Plus Therapeutics position peaked at $181 in Q1 2024.
  • 9 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.